According to Report, the global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030 and is anticipated to grow at a CAGR of 10.6% from 2021 to 2030.
According to Report, the global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030 and is anticipated to grow at a CAGR of 10.6% from 2021 to 2030.
Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and a reduction in the recurrence rate of tumor post chemotherapy.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38822
Rising R&D activities in the cancer immunotherapy field is resulting in the introduction of advanced variants with enhanced efficacy and effectiveness of treatment. Immuno-oncology have shown promising results with improved survival and lower toxicity. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.
By Product Analysis
Monoclonal antibodies (mAbs) were the most prominent product segment in 2021. Increasing investments in R&D of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new avenues of revenue generation for companies that provide oncology therapeutics.
Immunomodulators, unlike other chemo-immunotherapy drugs, are used to modulate immune system of patients, which in turn, enhance the activity of immune system against tumors.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 130.6 Bn by 2030 |
| Growth Rate | CAGR of 10.6% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, cancer type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | F. Hoffmann-La Roche, Ltd; AstraZeneca; Bristol-Myers Squibb Company; Pfizer, Inc.; Merck & Co., Inc.; Novartis AG. |
By Cancer Type Analysis
By type, the global cancer immunotherapy market has been segmented into lung, breast, colorectal, melanoma, prostate, head & neck, ovarian, and pancreatic cancer. Majority of immunotherapy drugs including few monoclonal antibodies and checkpoint inhibitors are approved for treatment of NSCLC.
Checkpoint inhibitors are used as a first-line treatment in patients suffering from advanced lung tumor. Opdivo, Keytruda, and Tecentriq are immunotherapeutic drugs approved for lung tumor.
Cancer immunotherapies are being increasingly used for melanoma therapeutics. The growth of the melanoma segment can be attributed to development of new products, large number of FDA approvals, and extensive R&D in this field.
By Regional Analysis
North America held the largest revenue share in 2021. Rising incidence of the disease, increasing ease of access to modern therapeutics, coupled with expanding geriatric population, are contributing to the growth of the regional market.
Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs are being introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies.
COVID-19 Impact
With the rising COVID-19 pandemic, the market is expected to be negatively impacted due to the shortage and irregular supply of cancer immunotherapy products. This might allow local manufacturers to increase their presence in the market. Additionally, some biopharmaceutical companies, such as Merck & Co. Inc., and Eli Lilly and Company had announced clinical trial delays. For instance, the data from ClinicalTrials.gov has shown that more than 200 interventional oncology studies were suspended in March and April 2020, as a result of the COVID-19 crisis. Also, 60% of institutions in the United States and 86% in Europe are enrolling new patients at a lower rate. Therefore, globally the companies are focused on the development of drug or vaccine especially immunotherapy-based drug for COVID-19 because immunotherapy is highly effective, which act by stimulating patients to own immune system, which is expected to impact on the market growth for a short period of time.
Key Players
The key players operating in the market are Amgen Inc., AstraZeneca, F. Hoffman La Roche, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Merck and Co., Novartis and Pfizer.
Market Segmentation
- By Product
- Monoclonal Antibodies
- Immunomodulators
- Oncolytic Viral Therapies and Cancer Vaccines
- By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38822
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333